Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Evommune, Inc.

NYSE: EVMN · Life Sciences · 7 alerts · CIK 2044725

Share price
$7.10Close, Nov 16
Market cap
$294M
Shares outstanding
41.35MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Evommune, Inc. filings on SEC EDGAR ↗

6:32 AM ET 8-K
Licensing Deal

Evommune Licensing Deal with Hinova Pharmaceuticals Inc.

Evommune announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals for EVO570, an oral VAV1-directed molecular glue degrader. Evommune acquired worldwide rights (excluding Greater China) to develop, manufacture, and commercialize the candidate, which it plans to develop for rheumatoid arthritis.

Counterparty
Hinova Pharmaceuticals Inc.
5:11 PM ET 8-K
Licensing Deal

Evommune Licensing Deal with Hinova Pharmaceuticals Inc. Worth $30M

Evommune has entered into an exclusive license agreement with Hinova Pharmaceuticals to develop and commercialize EVO570, a VAV1 molecular glue degrader, globally excluding Greater China. Evommune will pay $20 million upfront in cash and $10 million in pre-funded warrants, with Hinova eligible for up to $1.07 billion in additional milestone payments plus tiered royalties.

Value
$30M
Counterparty
Hinova Pharmaceuticals Inc.
Term
Royalty Term

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.